Actavis
Patently problematic? The impact of the Eli Lilly/Actavis intellectual property battle
September 4, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Eli Lilly, biotech, drugs, pemetrexed, pharma, pharmaceutical
The UK Supreme Court has sent shockwaves through the intellectual property world with its recent decision on Eli Lilly v …
Gilead to launch injunction against Mylan and Actavis over HIV generics in Ireland
July 6, 2017Sales and Marketing Actavis, Gilead, HIV, Mylan, Truvada
Gilead is expected to launch injunctive action against rivals Mylan and Actavis over the allegation that they are planning to …
Five most talked about mergers and acquisitions of 2016
January 27, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Bayer, Boehringer, Johnson & Johnson, Sanofi, Teva, acquisition, mergers, monsanto, pharma
2017 has kicked off with a bang – as Johnson & Johnson confirmed a $30 billion deal to takeover of …
Actavis UK overcharged NHS with 12,000% price hike, watchdog says
December 16, 2016Medical Communications, Sales and Marketing Actavis, CMA, NHS
Actavis UK has been accused by the Competition and Markets Authority (CMA) of overcharging the NHS by selling its hydrocortisone …
Pfizer loses UK patent infringement case over $5.1bn drug
October 13, 2016Medical Communications, Sales and Marketing Actavis, Lyrica, Pfizer, patent infringement, pregabalin
Pfizer has been dealt a significant blow as the UK Court of Appeal has rejected the company’s patent infringement claims …
Top ten stories in the pharmaceutical industry this week
August 5, 2016Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten
It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …
Teva completes $40 billion acquisition of Actavis Generics
August 3, 2016Research and Development, Sales and Marketing Actavis, Allergan, Teva, acqusition, generics
Teva has announced that it has completed its acquisition of Actavis Generics, a subsidiary of Allergan, in a transaction valued …
German Supreme Court grants Lilly appeal to block Alimta generics
June 15, 2016Research and Development, Sales and Marketing Actavis, Alimta, Eli Lilly
Eli Lilly (NYSE: LLY) has announced that it has been granted an appeal by the German Federal Supreme Court, in …
Lilly suffers damaging Alimta patent blow
February 15, 2016Manufacturing and Production, Sales and Marketing Actavis, Alimta, Allergan, Eli Lilly, pemetrexed
Eli Lilly says it plans to appeal a UK High Court’s verdict that could imminently open its blockbuster lung cancer …
Bayer takes on Actavis in ABPI code conduct breach
November 26, 2015Medical Communications, Sales and Marketing ABPI, Actavis, Bayer, PMCPA
The Prescription Medicines Code of Practice Authority (PMCPA) has ruled in favour of Bayer in a case brought against Actavis. …
Pfizer in ‘friendly’ merger talks with Allergan
October 29, 2015Sales and Marketing Actavis, Allergan, Pfizer, Teva
Pfizer is in talks with Allergan over what could be the largest takeover deal in an already record-breaking year, it …
High Court rules against Pfizer in Lyrica patent case
September 10, 2015Medical Communications, Sales and Marketing Actavis, Lyrica, Pfizer, anxiety, epilepsy, generics, neuropathic pain, pregabalin
The High Court of England and Wales today ruled against Pfizer in the patent battle with Actavis on Pfizer’s blockbuster …
Takeda in Velcade patent blow
August 25, 2015Manufacturing and Production Actavis, Sandoz, Takeda, Velcade, bortezomib, ixazomib
Takeda has lost a court case contesting the patent for its blockbuster multiple myeloma drug Velcade, in a decision that …
Allergan closing manufacturing facility in Iceland
July 14, 2015Manufacturing and Production Actavis, Allergan, Iceland, manufacturing, production, redundancies
Actavis is shutting a plant in Iceland, where its recently-acquired company Actavis has roots, and cutting 300 jobs in the …
Actavis contraceptives recalled after packaging errors
July 9, 2015Manufacturing and Production Actavis, FDA, manufacturing, packaging, product recall, production, recalls
Actavis is voluntarily recalling more than half a million boxes of contraceptive pills in the United States due to problems …
Latest content
